Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Grownvalve Gmbh |
| Country | Germany |
| Start Date | Apr 01, 2022 |
| End Date | Mar 31, 2025 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190188598 |
Each year 400,000 people are born with heart valve defects worldwide. Moreover, in the western world, 1 in 8 healthy adults will develop a heart valve problem during their lifetime.
Current artificial heart valves made from animal or human donor tissue carry a high risk of tissue rejection, degradation and calcification that limit their lifespan to about 10-years, forcing patients to undergo risky cardiac re-surgery.
For children, no dedicated valve product exists, thus, paediatric patients can endure 4-5 surgeries between 0-18-years of age as their bodies outgrow each replacement heart valve.
At GrOwnValve we have developed a paradigm shift in heart valve technology: the first autologous valve, grown from the patient’s own tissue, crafted using medical imaging and a 3D printing technique.
Our valve lasts a lifetime, eliminating tissue rejection and surgical risks associated with repeated surgery (bleeding, infection and death).
Grownvalve Gmbh
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant